US Patent
US10918694 — Topical cyclosporine-containing formulations and uses thereof
Formulation · Assigned to Sun Pharma Global FZE · Expires 2037-02-28 · 11y remaining
Vulnerability score
42/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects topical ophthalmic formulations containing cyclosporine in specific concentrations, along with methods for making and using these formulations.
USPTO Abstract
Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.